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STUDY PROTOCOL Open Access
The Odon Device™ for assisted vaginal
birth: a feasibility study to investigate
safety and efficacy—The ASSIST II study
Emily J. Hotton1,2* , Mary Alvarez2,3, Erik Lenguerrand1, Julia Wade3, Natalie S. Blencowe4,5, Tim J. Draycott2,
Joanna F. Crofts2 and The ASSIST II Study Group
Abstract
Background: The Odon Device™ is a new device for assisted vaginal birth that employs an air cuff around the fetal
head for traction. Assisted vaginal birth (AVB) is a vital health intervention that can result in better outcomes for
mothers and their babies when complications arise in the second stage of labour. Unfortunately, instruments for AVB
(forceps and ventouse) are often not used in settings where there is most clinical need often due to lack of training
and resources, resulting in maternal and neonatal morbidity and mortality which could have been prevented.
This is often due to a lack of trained operators as well as difficulties in the sterilisation and maintenance of AVB devices.
This novel, single use device has the potential to mitigate these difficulties as it is single use and is potentially simpler
to use than forceps and ventouse.
All the studies of the Odon Device to date (pre-clinical, preliminary developmental and clinical) suggest that the Odon
Device does not present a higher risk to mothers or babies compared to current standard care, and recruitment to
intrapartum research exploring the device is feasible and acceptable to women. The first study in which the Odon
Device was used in clinically indicated conditions (the ASSIST Study) reported a lower efficacy than those reported with
established devices. The reasons need to be explored, specifically focussing on learning curve, the technique of the
doctors using this new device and potential modifications to device design. A follow-on clinical study to further
investigate the efficacy and safety of the Odon Device in its indicated use, the ASSIST II Study, is therefore being
undertaken.
Methods: The primary feasibility outcome is study feasibility (recruitment and retention rates) whilst the primary
clinical outcome successful vaginal birth completed with the Odon Device. Key secondary feasibility outcomes include
participant withdrawal, compliance in data collection and acceptability of the device to women and operators.
Secondary clinical outcomes include maternal, neonatal and device outcomes. Safety data will be reviewed following
every birth exploring maternal, neonatal and device risks. Using A’Hern approach for sample size calculation, we aim to
recruit 104 women requiring an assisted vaginal birth for a recognised clinical indication. Assuming an AVB success rate
of 65% or more, a one-sided alpha risk of 5% and power of 90%.
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Discussion: The data from the ASSIST II Study will provide the information required regarding acceptability,
recruitment, outcome data collection, device design, technique of device use and operator learning curve in order to
design a future randomised controlled trial of the Odon Device versus current modes of assisted vaginal birth.
Trial registration: ISRCTN registration: 38829082 (prospectively registered July 26, 2019)
Keywords: Assisted vaginal birth, Obstetrical vacuum extraction, Obstetrical extraction, Odon Device, Obstetrical
forceps, Feasibility studies, Device safety, Medical devices
Background
No new methods of assisting vaginal birth have been intro-
duced into clinical practice since the development of the
ventouse in the 1950s, despite the huge advances in medical
care over the past 70 years. Complications of the second
stage of labour remain a major cause of maternal and neo-
natal morbidity and mortality. Assisted vaginal birth (AVB)
reduces adverse outcomes for women and their babies rela-
tive to a caesarean section performed in the second stage of
labour [1]. There is significant variation in the rates of AVB
worldwide, with many low- and middle-income countries
reporting that AVB is not utilised at all [2]. AVB is currently
performed regularly (10 to 15% of births) in the UK, Spain,
France, Ireland, Portugal, Canada and Australia, occasionally
in the Netherlands, Sweden and Algeria (5 to 10% of births),
and rarely (less than 5% of births) in the USA, India and
most low- and middle-income countries [3–6].
Currently, a vaginal birth may be expedited through
the use of obstetric forceps or ventouse. Forceps are
more likely to achieve an AVB when compared to a ven-
touse; however, they are associated with increased ma-
ternal perineal and vaginal trauma. The ventouse is
more likely to fail than forceps and is associated with an
increased risk of neonatal cephalohaematoma and retinal
haemorrhage [7].
The Odon Device is a new device for AVB, comprising
two main components: a polyethylene sleeve and a plas-
tic applicator (Fig. 1). The applicator consists of a handle
with four pronged flexible spatulas that slide around the
fetal head to position the sleeve. The applicator has a
progress indicator allowing the operator to check when
the correct depth of insertion has been reached. The
sleeve contains a circumferential air chamber that is in-
flated around the fetal head. The use of an air chamber
to act as the traction point on the fetal head is hypothe-
cated to reduce adverse events associated with the
greater pressures applied to the fetal head during the use
of forceps. The lack of negative pressure on the fetal
head, the mechanism of action of the ventouse, is de-
signed to eliminate vacuum-associated haematoma and
haemorrhage. These contentions have been supported in
pre-clinical simulation studies [8–10].
The first in human pilot study of four earlier versions
of the Odon Device in 49 healthy volunteers in
Argentina and South Africa [11]. Further extensive
simulation and human factors studies were performed to
investigate safety and usability [12].
The ASSIST Study (conducted between October 2018
and April 2019) was the first study in which the Odon
Device was used to assist vaginal birth for clinically
indicted conditions (e.g. in cases of prolonged second
stage of labour or presumed fetal compromise) [13, 14].
All the studies of the Odon Device to date (pre-clin-
ical, preliminary developmental and clinical) suggest that
the Odon Device does not present a higher risk to
mothers or babies compared to current standard care
Fig. 1 The Odon Device component parts
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(forceps and ventouse). However, the number of births
assisted to date with the device is small and more ex-
perience of using the device is required to generate an
evidence based safety profile. Furthermore, the reasons
for the lower than expected success rate of the device
needs to be explored, specifically focussing on obstetri-
cian learning curves and the potential need for modifica-
tions to device design. A follow-on feasibility study to
further investigate the efficacy and safety of the Odon
Device in its indicated use, the ASSIST II Study has
therefore been designed.
Methods/design
The main aim of the study is to assess the feasibility of
conducting a definitive trial in terms of recruitment and
acceptability of the intervention, follow-up and data col-
lection methods. In addition, the study aims to explore
successful vaginal birth completed with the Odon
Device.
Objectives
(i) To estimate feasible eligibility, recruitment as well
as refusal and follow-up rates
(ii) To investigate the feasibility of collecting data as
well as exploring the safety and efficacy of forceps
and ventouse from women who did not receive the
Odon Device
(iii)To investigate the safety, efficacy and acceptability
of a new device for the Odon Device
(iv)To define the clinical circumstances in which the
device is most effective.
(v) To study the learning curve of the operator and to
investigate the most effective user technique.
(vi)To study the device design and functionality.
Study design
The ASSIST II Study (Assisted Vaginal Birth Study) is a
non-randomised feasibility study of women who require
an AVB for a recognised clinical indication. The study
also includes a nested cohort study of women and babies
who had a ‘missed’ Odon Device assisted birth. These
cases comprise women who have consented to partici-
pate in the ASSIST II Study and require an AVB but are
unable to have a Odon Device assisted birth due to op-
erator availability. The inclusion of the nested cohort
will explore the feasibility of collecting information from
a ‘comparator group’. The information gained from this
study will be used to plan a large randomised controlled
trial that will directly compare the Odon Device with the
ventouse.
The key changes to the ASSIST II Study protocol as
compared to the ASSIST Study protocol are as follows:
 Refined participant inclusion criteria to exclude very
complex births when the vertex is at the level of the
ischial spines.
 Inclusion of a nested cohort of ‘missed’ births.
 Larger sample size to support investigation into
efficacy (104 births compared to 40).
 Manufacturer will ensure the device is manufactured
to the required specification to avoid malfunction of
the bulb pump experienced in the ASSIST Study.
 A simplified clinical primary outcome.
 Streamline changes to the data collection forms.
A CONSORT diagram of the ASSIST II Study is
shown in Fig. 2.
Population/sample
Participants will be pregnant women aiming for a va-
ginal birth who plan to give birth at North Bristol
NHS Trust (NBT), Bristol, UK. Recruitment is pro-
jected to continue for 11 months (due to the AVB
rate within the department) after which time it is es-
timated that 104 sets of clinical primary outcome data
will have been recorded.
Prospective participants will receive information on
the study in early pregnancy (12 to 28 weeks) via the
NBT Maternity ‘App’ (this ‘App’ is provided to all
pregnant women at NBT and provides information on
all aspects of their maternity care) and paper infor-
mation leaflets, given to women at any hospital ad-
mission. Members of the study team will then
approach women after 28 completed weeks of preg-
nancy during antenatal appointments or antenatal ad-
missions, to discuss the study and offer women the
opportunity to watch a video explaining the study.
Women who are willing to take part (should they re-
quire an AVB) will then be invited to provide in-
formed written consent. Figure 3 demonstrates the
SPIRIT figure outlining the schedule of enrolment, in-
terventions and assessments. SPIRIT checklist can be
found in Additional file 1.
When a woman who has previously consented to
participate in the study arrives on the labour ward,
her eligibility to participate in the study will be
rechecked and verbal re-confirmation of her consent
to take part in the study will be sought by a midwife
and obstetrician.
Inclusion and exclusion criteria
Women will be able to participate in the ASSIST II
Study if all of the following apply at initial consent: ≥18
years of age; singleton pregnancy of at least 36 weeks’
gestation; negative antenatal screen for HIV and
Hepatitis B; in active labour and requiring an assisted
vaginal birth for a clinical indication (as per the Royal
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College of Obstetricians & Gynaecologists (RCOG)
Greentop Guideline 26) [7]: the vertex is 1 cm or
more below the ischial spines; the woman has effect-
ive analgesia in place during the use of the instru-
ment (i.e. epidural, spinal or pudendal block, or
perineal infiltration with local anesthetic), and there is
no obstetric indication for an alternative method of
AVB).
Women will not be able to take part in the ASSIST
II Study if there is the fetal vertex at or above the is-
chial spines, a diagnosis of a fetal skull abnormality
(i.e. macrocephaly) or osteogenesis imperfecta, suspi-
cion of a fetal bleeding disorder (von Willebrand’s
disease, AITP, haemophilia), an intrauterine fetal
death in the current pregnancy, the woman is sensi-
tive to latex, the woman is currently serving a prison
sentence, and there is a fetal bradycardia which is on-
going and has not recovered.
Intervention
If the woman agrees to an AVB, an accoucheur who
has had specific training in using the Odon Device
will assist the birth with the Odon Device. Should the
birth not be achieved with the Odon Device, the
obstetrician will use their clinical judgement on an in-
dividual case basis to complete the birth using ven-
touse, forceps or caesarean section as appropriate.
Primary, secondary and safety data will be gathered
regarding the assisted birth and use of the device
with additional qualitative investigation of recruitment
processes to the study.
Nested cohort
If an obstetrician who has had specific training in
using the Odon Device is not available to attend the
birth of an eligible and consented woman, the
woman and her baby will be included in the nested
cohort group. The birth will be assisted by the on-
call team as per routine care in the maternity unit.
All birth and outcome data will be gathered regard-




Study feasibility through descriptions of recruitment and
retention rates of women who may require an AVB at
the end of their labour.
Fig. 2 CONSORT diagram of the ASSIST II Study
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Additional feasibility outcomes
As well as recruitment rates, the following feasibility
outcomes will be explored in detail:
 Follow-up rates and reasons for declining or
withdrawal (medical, personal, logistic, others).
 Suitability of outcome measures and overall data
collection processes, including complete list of data
collection and recruitment rate to the study.
 Ability to collate data from a ‘nested’ cohort will
help demonstrate whether collecting data on a
control group in a RCT is feasible.
Patient acceptability will be assessed through the pa-
tient perception score of birth experience days 1, 7 and
28 postnatal (score out of 15 where 3 is the lowest score
possible) and through qualitative assessment.
Practitioner acceptability will be assessed through per-
ceived outcomes following each attempted AVB. The
following will be collected on a 5-point Likert scale.
 Instrument of choice if Odon Device was not used
(rotational forceps/non-rotational forceps/KIWI
ventouse/silastic ventouse).
 Perceived overall ease of use of device (for all
AVBs).
 Ease of device set-up (for all AVBs).
 Ease of device application to the baby’s head (for all
AVBs).
 Ease of withdrawal of the applicator after application
(for Odon births only).
 Comfort with the level of force required to assist the
birth of the baby (for all AVBs).
 Ease of deflation of the cuff prior to crowning (for
Odon births only).
 Ease of removal of the forceps or ventouse.
In order to further understand the technique for de-
vice use, any birth with the Odon Device, the practi-
tioner (and research midwife if present) will document
the angle of device application using a grid stating
Fig. 3 SPIRIT figure: schedule of enrolment, interventions and assessments
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whether the handle of the device is pointing: up, down
or horizontally.
Clinical primary outcome: proportion of births successfully
assisted with the Odon Device
A birth will be defined as ‘successful’ if all of the follow-
ing criteria are met:
1. The birth of the baby is expedited with the Odon
Device.
2. There are no serious maternal adverse reactions
related to the use of the device during birth.
3. There are no serious neonatal adverse reactions
related to the use of the device during birth
(Table 1).
Secondary clinical outcomes
Secondary outcome measures are categorised below and
include measures needed to ascertain the feasibility of a
future RCT:
Birth
 Time from ‘decision to perform assisted birth’ to
‘birth’ (minutes).
 Time from ‘device application” to ‘birth’ (minutes).
 Time between ‘decision to perform assisted birth’ to
‘time of Odon application’.
 Location of birth.
 Mode of birth following failed use of Odon device.
Device
 Failure of a component of the Odon Device.
 Number of applications of device.
 Number of pulls of the device.
 Any trauma caused by first device application.
 Perceived reason for device failure from operator
(maternal/clinical/device/other).
Maternal
 Weighed blood loss.
 Perineal and anal sphincter injury (1st/2nd/3rd/4th
degree tears and episiotomy).
 Ischio-rectal fossa defect.
 Cervical tear (present not requiring suturing).
 Cervical tear (present requiring suturing).
 Labial tear requiring suturing.
 Lower segment caesarean section performed (Yes/No).
 Use of analgesia days 1, 7 and 28 postnatal.
 Details of analgesia used at days 1, 7 and 28
postnatal.
 Maternal death.
 Length of hospital stay following birth.
Neonatal
 Umbilical artery pH and base excess.
 Umbilical vein pH and base excess.
 Shoulder dystocia.
 Apgar scores at 1, 5 and 10 min post birth.
 Neonatal Infant Pain Scores at 2 and 6 h post birth.
 Neonatal feed by 10 h post birth.
 Method of feeding days 1, 7, 28 and 90 post birth.
 Admission to Neonatal Intensive Care Unit (NICU).
 Time spent in NICU (hours).
 Neonatal soft tissue trauma (bruise/scalp/facial
injury/cephalohaematoma).
 Neonatal vascular injury (subaponeurotic
haemorrhage).
 Neonatal body maps (head and neck).
 Neonatal skeletal injury (bone fracture).
 Neonatal intra-cranial injury (cerebral contusion).
 Neonatal neurological injury still present at day 28
post birth.
 Neonatal seizure by day 28 post birth.
 Phototherapy for jaundice contributed to by bruising
by day 28 post birth.
 Anaemia requiring transfusion by day 28 post birth.
 Neonatal encephalopathy requiring therapeutic
hypothermia within 28 days post birth.
 Organ failure within 28 days post birth.
 Other neonatal injury.
 Neonatal death within 28 days post birth.
Table 1 Primary outcome for the ASSIST II Study
Criteria Source Collected by
The birth of the baby is expedited with the Odon Device AVB pro forma
Medical notes
Research team member including device operator
There are no serious maternal adverse events related to
the use of the device during birth
AVB pro forma
Medical notes
Research team member including device operator
There are no serious neonatal adverse events related to
the use of the device during birth
AVB pro forma
Medical notes
Research team member including device operator
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Patient-reported outcomes
 Maternal health-related quality of life data (EQ-5D-
5L) will be collected during the antenatal period and
at day 1 and day 28 postnatal.
 Maternal perception of pain (11-point Likert scale)
at days 1, 7 and 28 postnatal.
 Maternal continence at day 90 postnatal.
Health utilisation form outcomes
Data regarding visits to a health care professional in ei-
ther the hospital or community setting within the first
28 days postnatal will be collected.
Safety of intervention
A comprehensive assessment of the safety of the Odon
Device will be undertaken following every attempted
birth within the ASSIST II Study. Outcome measures
and data collected will ensure capture of any potential
adverse events associated with the Odon Device at time
of birth by the operator and/or a member of the re-
search team. All follow-ups will be performed by the re-
search team. In the immediate postpartum period a
member of the research team will follow-up the partici-
pant on a daily basis until discharge, collecting the day
one data. To ensure that any serious adverse events that
occur in the postnatal period are captured, an Adverse
Event Reporting System will be initiated, for ward staff
to highlight any adverse events that occur after birth. In
addition, device failure (or failure of any component) will
be reported as an individual outcome measure. Follow-
ups at days 7, 28 and 90 will be conducted by a member
of the research team telephoning the woman using their
contact details provided to the study team. The Trial
Management Group (TMG) and Sponsor will regularly
review data from all births to ensure early identification
of any trends of adverse events. All adverse events will
be classified and reported according to the schedule of
the Medicines and Healthcare Regulation Agency
(MHRA) and the Research Ethics Committee.
Patient and public involvement
Women and their partners have been involved in the de-
velopment of the feasibility ASSIST II Study prior to the
submission for research approvals—patient and public
involvement (PPI) has reviewed the proposed study de-
sign, as well as woman-facing documentation (leaflets,
videos and consent forms) and has supported both the
general and specific aims of the study. A lay patient rep-
resentative will be a member of the Trial Steering Com-
mittee (TSC) for the ASSIST II Study.
Analysis
Investigators had established a priori threshold for spe-
cific feasibility and acceptability criteria. These were the
following: (i) the proportion of eligible women agreeing
to participate in the study would be 54% or greater (the
threshold for the first clinical trial of the Odon Device
[11]), (ii) retention would be 90% of greater, (iii) at least
95% of women had a positive birth satisfaction score at
day one postnatal and (iv) at least 95% of practitioners
had a positive opinion on the use of the Odon Device.
The feasibility outcomes will be reported descriptively
and narratively. Reasons for ineligibility, refusal, lost-to-
follow-up or missing data will be categorised and de-
scribed as frequencies. Women and their babies will be
followed up at 1 day, 7 days, 28 days and 90 days follow-
ing the birth. A woman and her baby will be deemed to
complete their participation in the study at 90 days after
the birth.
Clinical outcomes will be reported as frequency and
proportion, mean (standard deviation) or median (inter-
quartile range) depending on their nature and distribu-
tion. The overall rate of successful AVB birth will be
reported and the frequency of unsuccessful births will be
reported by the three criteria defined for success. The
overall number of safety events will be reported, as well
as the number of events, by main reasons for adverse
events. Events related to the device failure and/or mis-
use of the device will also be described.
Integrated qualitative research
In ASSIST II Study the integrated qualitative study
(IQS) will focus exclusively on optimum processes for
providing information about and obtaining informed
consent for research studies that involve interventions
that may be initiated in the intrapartum period.
The aims of the IQS are to evaluate the model of in-
formation provision and receiving informed consent de-
veloped for the ASSIST II (comprising the ASSIST II
Study information video embedded within informed
consent discussions with research midwives, developed
based on findings of a study evaluating information
provision processes within the ASSIST Study).
Data will include audio-recordings of recruitment dis-
cussions between research midwives and women eligible
to participate in the study and in-depth interviews with
both women who have been invited to participate in the
study and the research midwives involved in inviting
them to participate. Written consent from all partici-
pants will be obtained prior to any qualitative research
and verbal re-confirmation of consent will be obtained
prior to each audio recording and interview. Findings
will inform information provision during recruitment to
any future study involving the Odon Device.
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Sample size
Although a formal sample size is not required, the
A’Hern approach for sample size calculation was per-
formed in PASS (Power and Sample Size) software to
help judgement regarding an appropriate figure. Assum-
ing that the success rate (P) of a poor AVB is 50%, and
the success rate of a good AVB would be 65% or more,
and one-sided alpha risk of 5% and power of 90%, a
study with 104 participants will be required to decide
whether the success rate of the Odon Device is less than
or equal to 50%, or greater than or equal to 65%. The
success rate of 65% was identified from Attilakos et al.,
an AVB study conducted in the same unit as the ASSI
ST II Study which reported a success rate for a single-
use, hand-held ventouse device of 66% [15].
An interim safety analysis will be conducted to moni-
tor and check the maternal and neontatal safety data
only; no assessment of the Odon Device success will be
conducted at this interim point. The whole sample size
(n=104) will be required to pursue the understanding of
the device used in the clinical context of the study. This
safety interim analysis will be performed around the
42nd attempted birth using the Odon Device.
Trial oversight
The TMG consisting of all investigators, co-investigators
and Sponsor will be responsible for the day-to-day run-
ning of the study. The study will be overseen by two
committees, the Independent Data Monitoring Commit-
tee (IDMC) and the Trial Steering Committee (TSC).
The IDMC will sit after the 42nd birth has been
attempted using the Odon Device. The IDMC will have
no direct involvement in the running of the trial. The
IDMC will generate a report on the performance of the
device and safety of participants. The TSC will consist of
an independent clinical expert, statistician and a lay rep-
resentative, together with the investigators and Sponsor
representative. The TSC will review all reports produced
by the IDMC and make a recommendation to the Spon-
sor following every review to continue, modify or halt
the study. The TSC will provide oversight of the pro-
gress of the study and ensure the study is conducted ac-
cording to the principles of Good Clinical Practice
(GCP). Auditing will take place when requested by the
Sponsor.
Dissemination
Study results will be published within one year of com-
pletion of data collection in an appropriate peer-
reviewed open-access journal. The results will be pre-
sented at local, national and international meetings.
Summaries will also be distributed using existing parent
networks. A summary of results will also be sent to all
women who participated in the study (including nested
cohort participants), unless they express their wish not
to receive such information. Results will be communi-
cated to a lay audience by social media activities of
North Bristol NHS Trust, University of Bristol and the
research team.
Discussion
An appropriately conducted AVB, performed when clin-
ically indicated, is associated with improved maternal
and neonatal outcomes when compared to caesarean
section in the second stage of labour or no action [1].
The ASSIST Study has demonstrated that it is feasible to
recruit women to an intrapartum research study explor-
ing novel device for AVB, with women, obstetricians and
midwives finding the device acceptable. There has been
no evidence of an increased risk to mothers or babies
when comparing the Odon Device to forceps or ven-
touse [13].
The success rate of the Odon Device was lower than
the reported success rates of both forceps and vacuum
and that of the initial pilot study [7, 11, 15]. However,
the ASSIST Study was the first time that the Odon De-
vice had been used in clinically indicated conditions. As-
pects that need to be further explored include the
clinical circumstances in which the device is used, the
technique of application and traction, the operators prior
experience of the device (learning curve) and the design
and functionality of the device itself. We believe that it
is therefore reasonable to proceed to a further feasibility
study of the Odon Device, and, if positive, a randomised
controlled trial.
If found safe by the TSC, IDMC and Sponsor, findings
from the ASSIST, ASSIST II Studies and parallel feasibil-
ity study in France [16] will inform the design of a ran-
domised controlled trial that may provide evidence that
supports the introduction of the device into clinical
practice as a new device for AVB.
Trial status
The ASSIST II Study commenced on the 9th of August
2019, using version 0.2 of the protocol. The study will
cease recruitment after 104 complete sets of primary
outcome data are received. This is projected to be in
June 2020.
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